PF4 IgG assay— 510(k) K201311

Substantially Equivalent

Immucor Gti Diagnostics, Inc.

FDA 510(k) clearance K201311 for PF4 IgG assay, Substantially Equivalent on 2020-06-18. Applicant: Immucor Gti Diagnostics, Inc.. Device class: 2.

Clearance details

Applicant: Immucor Gti Diagnostics, Inc.
Product code: Code LCO
Device class: Class 2
Regulation: 21 CFR 864.7695
Advisory panel: Hematology
Date received: 2020-05-18
Decision date: 2020-06-18
Decision: Substantially Equivalent
Clearance type: Special
Location: Waukesha, WI, US

Download summary PDF View on FDA.gov ↗

Recent devices under product code LCO

K243374 — HemosIL CL HIT-IgG(PF4-H)2025-01-28
K201570 — PF4 Enhanced assay2020-09-11
K170854 — HemosIL AcuStar HIT-IgG(PF4-H), HemosIL AcuStar HIT Controls2017-09-08
K153137 — HemosIL HIT-Ab(PF4-H), HemosIL HIT-Ab(PF4-H) Controls2016-07-08
K071781 — PF4 IGG2007-12-19

Data sourced from openFDA. This site is unofficial and independent of the FDA.